Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRAY-02 olomorasib plus immunotherapy in KRAS G12C-mutant NSCLC
ChiCTR2500099840Phase 3Not yet recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olomorasib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Jilin Provincial Cancer Hospital. Primary endpoints: Disease-free survival and Progression-free survival. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500099840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099840.